Survival trends in solid cancers in the Nordic countries through 50 years
Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking. We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden thr...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2022-11, Vol.175, p.77-85 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 85 |
|---|---|
| container_issue | |
| container_start_page | 77 |
| container_title | European journal of cancer (1990) |
| container_volume | 175 |
| creator | Hemminki, Janne Försti, Asta Hemminki, Akseli Hemminki, Kari |
| description | Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking.
We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970–2019) using the NORDCAN database.
The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10–20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30–50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40–50 % units) in prostate and kidney cancers but remained at 10–20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers.
The analysis over a half-century confirms the progress in ‘real-world’ cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.
[Display omitted]
•Relative survival was reported for all solid cancers through a half-century.•5-year survival was over 60% in about two-thirds of cancers, covering 84% of all patients.•During 50 years, 1- and 5-year survival increased up to 30 and 20% units, respectively.•The results showed a positive overall trend, but metastatic cancers remain a challenge.•Cure in cancers is possible before metastases appear underscoring early detection. |
| doi_str_mv | 10.1016/j.ejca.2022.08.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2714059311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804922004920</els_id><sourcerecordid>2754549572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-32d1ab1b9aab3f9d572f5357d600f55249afa8ed15f51c936eec0074941d6ef33</originalsourceid><addsrcrecordid>eNp9kM9O3DAQh62qqCy0L9ADitQLl6Rjx05iiQtC_Gm1ggP0bDn2pDjKxoudrMTb9Fl4Mrxd4MCB00ij7_eb0UfIdwoFBVr97AvsjS4YMFZAUwAVn8iCNrXMoRHsM1mAFDJvgMt9chBjDwB1w-EL2S8rkBVwWJDft3PYuI0esingaGPmxiz6wdnM6NFg-L-Y7jG79sE6kxk_j1NwGNMy-PnvfSbg6d8j6hC_kr1ODxG_vcxD8ufi_O7sKl_eXP46O13mhrNmyktmqW5pK7Vuy05aUbNOlKK2FUAnBONSd7pBS0UnqJFlhWjS41xyaivsyvKQHO9618E_zBgntXLR4DDoEf0cFaspByFLShP64x3a-zmM6btECS64TNcTxXaUCT7GgJ1aB7fS4VFRUFvTqldb02prWkGjkukUOnqpntsV2rfIq9oEnOwATC42DoOKxmFyal1AMynr3Uf9z8wzjo4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754549572</pqid></control><display><type>article</type><title>Survival trends in solid cancers in the Nordic countries through 50 years</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Hemminki, Janne ; Försti, Asta ; Hemminki, Akseli ; Hemminki, Kari</creator><creatorcontrib>Hemminki, Janne ; Försti, Asta ; Hemminki, Akseli ; Hemminki, Kari</creatorcontrib><description>Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking.
We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970–2019) using the NORDCAN database.
The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10–20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30–50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40–50 % units) in prostate and kidney cancers but remained at 10–20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers.
The analysis over a half-century confirms the progress in ‘real-world’ cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.
[Display omitted]
•Relative survival was reported for all solid cancers through a half-century.•5-year survival was over 60% in about two-thirds of cancers, covering 84% of all patients.•During 50 years, 1- and 5-year survival increased up to 30 and 20% units, respectively.•The results showed a positive overall trend, but metastatic cancers remain a challenge.•Cure in cancers is possible before metastases appear underscoring early detection.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2022.08.015</identifier><identifier>PMID: 36096040</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Age Distribution ; Cancer ; Cancer control ; Denmark ; Female ; Finland - epidemiology ; Follow-Up Studies ; Gallbladder ; Humans ; Immunotherapy ; Incidence ; Kidney cancer ; Kidneys ; Liver Neoplasms ; Male ; Melanoma ; Metastases ; Ovarian cancer ; Periodic survival ; Prognosis ; Prostate ; Registries ; Risk Factors ; Scandinavian and Nordic Countries - epidemiology ; Sex preferences ; Survival ; Survival Analysis ; Survival Rate ; Treatment</subject><ispartof>European journal of cancer (1990), 2022-11, Vol.175, p.77-85</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Nov 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-32d1ab1b9aab3f9d572f5357d600f55249afa8ed15f51c936eec0074941d6ef33</citedby><cites>FETCH-LOGICAL-c428t-32d1ab1b9aab3f9d572f5357d600f55249afa8ed15f51c936eec0074941d6ef33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2022.08.015$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36096040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hemminki, Janne</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Hemminki, Kari</creatorcontrib><title>Survival trends in solid cancers in the Nordic countries through 50 years</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking.
We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970–2019) using the NORDCAN database.
The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10–20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30–50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40–50 % units) in prostate and kidney cancers but remained at 10–20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers.
The analysis over a half-century confirms the progress in ‘real-world’ cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.
[Display omitted]
•Relative survival was reported for all solid cancers through a half-century.•5-year survival was over 60% in about two-thirds of cancers, covering 84% of all patients.•During 50 years, 1- and 5-year survival increased up to 30 and 20% units, respectively.•The results showed a positive overall trend, but metastatic cancers remain a challenge.•Cure in cancers is possible before metastases appear underscoring early detection.</description><subject>Age Distribution</subject><subject>Cancer</subject><subject>Cancer control</subject><subject>Denmark</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>Follow-Up Studies</subject><subject>Gallbladder</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Incidence</subject><subject>Kidney cancer</subject><subject>Kidneys</subject><subject>Liver Neoplasms</subject><subject>Male</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Ovarian cancer</subject><subject>Periodic survival</subject><subject>Prognosis</subject><subject>Prostate</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Scandinavian and Nordic Countries - epidemiology</subject><subject>Sex preferences</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Treatment</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9O3DAQh62qqCy0L9ADitQLl6Rjx05iiQtC_Gm1ggP0bDn2pDjKxoudrMTb9Fl4Mrxd4MCB00ij7_eb0UfIdwoFBVr97AvsjS4YMFZAUwAVn8iCNrXMoRHsM1mAFDJvgMt9chBjDwB1w-EL2S8rkBVwWJDft3PYuI0esingaGPmxiz6wdnM6NFg-L-Y7jG79sE6kxk_j1NwGNMy-PnvfSbg6d8j6hC_kr1ODxG_vcxD8ufi_O7sKl_eXP46O13mhrNmyktmqW5pK7Vuy05aUbNOlKK2FUAnBONSd7pBS0UnqJFlhWjS41xyaivsyvKQHO9618E_zBgntXLR4DDoEf0cFaspByFLShP64x3a-zmM6btECS64TNcTxXaUCT7GgJ1aB7fS4VFRUFvTqldb02prWkGjkukUOnqpntsV2rfIq9oEnOwATC42DoOKxmFyal1AMynr3Uf9z8wzjo4</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Hemminki, Janne</creator><creator>Försti, Asta</creator><creator>Hemminki, Akseli</creator><creator>Hemminki, Kari</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202211</creationdate><title>Survival trends in solid cancers in the Nordic countries through 50 years</title><author>Hemminki, Janne ; Försti, Asta ; Hemminki, Akseli ; Hemminki, Kari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-32d1ab1b9aab3f9d572f5357d600f55249afa8ed15f51c936eec0074941d6ef33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age Distribution</topic><topic>Cancer</topic><topic>Cancer control</topic><topic>Denmark</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>Follow-Up Studies</topic><topic>Gallbladder</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Incidence</topic><topic>Kidney cancer</topic><topic>Kidneys</topic><topic>Liver Neoplasms</topic><topic>Male</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Ovarian cancer</topic><topic>Periodic survival</topic><topic>Prognosis</topic><topic>Prostate</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Scandinavian and Nordic Countries - epidemiology</topic><topic>Sex preferences</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hemminki, Janne</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Hemminki, Kari</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hemminki, Janne</au><au>Försti, Asta</au><au>Hemminki, Akseli</au><au>Hemminki, Kari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival trends in solid cancers in the Nordic countries through 50 years</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2022-11</date><risdate>2022</risdate><volume>175</volume><spage>77</spage><epage>85</epage><pages>77-85</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Global survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking.
We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970–2019) using the NORDCAN database.
The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10–20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30–50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40–50 % units) in prostate and kidney cancers but remained at 10–20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers.
The analysis over a half-century confirms the progress in ‘real-world’ cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.
[Display omitted]
•Relative survival was reported for all solid cancers through a half-century.•5-year survival was over 60% in about two-thirds of cancers, covering 84% of all patients.•During 50 years, 1- and 5-year survival increased up to 30 and 20% units, respectively.•The results showed a positive overall trend, but metastatic cancers remain a challenge.•Cure in cancers is possible before metastases appear underscoring early detection.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36096040</pmid><doi>10.1016/j.ejca.2022.08.015</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2022-11, Vol.175, p.77-85 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2714059311 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Age Distribution Cancer Cancer control Denmark Female Finland - epidemiology Follow-Up Studies Gallbladder Humans Immunotherapy Incidence Kidney cancer Kidneys Liver Neoplasms Male Melanoma Metastases Ovarian cancer Periodic survival Prognosis Prostate Registries Risk Factors Scandinavian and Nordic Countries - epidemiology Sex preferences Survival Survival Analysis Survival Rate Treatment |
| title | Survival trends in solid cancers in the Nordic countries through 50 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T08%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20trends%20in%20solid%20cancers%20in%20the%20Nordic%20countries%20through%2050%C2%A0years&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Hemminki,%20Janne&rft.date=2022-11&rft.volume=175&rft.spage=77&rft.epage=85&rft.pages=77-85&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2022.08.015&rft_dat=%3Cproquest_cross%3E2754549572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754549572&rft_id=info:pmid/36096040&rft_els_id=S0959804922004920&rfr_iscdi=true |